









市場行情
/
股票
/
nasdaq-tcrx
/

TScan Therapeutics Inc

TCRX

0.896USD

-0.035-3.79%

收盤 12/19, 16:00（美東）報價延遲15分鐘

50.83M總市值

虧損本益比TTM



TScan Therapeutics Inc

0.896

-0.035-3.79%

概覽公司財務分析

概覽

公司

財務

分析

關於 TScan Therapeutics Inc 公司

TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation. The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company has developed and continues to build its ImmunoBank with TCRs across different targets and human leukocyte antigens types to enable customized multiplex TCR-T therapy. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204. Its hematologic malignancies programs include TSC-100, TSC-101, and TSC-102.

TScan Therapeutics Inc簡介



公司代碼TCRX

公司名稱TScan Therapeutics Inc

上市日期Jul 16, 2021

CEOMacbeath (Gavin)

員工數量194

證券類型Ordinary Share

年結日Jul 16

公司地址830 Winter Street

城市WALTHAM

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02451

電話18573999500

網址https://www.tscan.com

公司代碼TCRX

上市日期Jul 16, 2021

CEOMacbeath (Gavin)

TScan Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Zoran Zdraveski, J.D., Ph.D.

Chief Legal and Strategy Officer, Secretary

84.61K

+1694.13%

Mr. Gavin Macbeath, Ph.D.

Chief Executive Officer, Director

49.77K

Mr. Garry A. Nicholson

Independent Director

Mr. R. Keith Woods

Independent Director

Dr. Stephen R. Biggar, M.D., Ph.D.

Independent Non-Executive Chairman of the Board

Jason A. Amello ,

Chief Financial Officer, Treasurer

Dr. Chrystal U. Louis

Chief Medical Officer

Ms. Katina Dorton

Independent Director

Dr. Barbara J. Klencke, M.D.

Independent Director

Dr. Gabriela Gruia, M.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Zoran Zdraveski, J.D., Ph.D.

Chief Legal and Strategy Officer, Secretary

84.61K

+1694.13%

Mr. Gavin Macbeath, Ph.D.

Chief Executive Officer, Director

49.77K

Mr. Garry A. Nicholson

Independent Director

Mr. R. Keith Woods

Independent Director

Dr. Stephen R. Biggar, M.D., Ph.D.

Independent Non-Executive Chairman of the Board

Jason A. Amello ,

Chief Financial Officer, Treasurer

收入明細

FY2025Q2

FY2025Q1

FY2024

FY2023

FY2022

FY2021

由於公司未披露，未能獲取相關數據

地區USD

名稱

營收

佔比

United States

3.08M

0.00%

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 12月4日週四

持股股東

股東類型

持股股東

佔比

Lynx1 Capital Advisors LLC

14.97%

BVF Partners L.P.

9.96%

K2 HealthVentures LLC

6.87%

Simplify Asset Management Inc

5.41%

Baker Bros. Advisors LP

5.31%

其他

57.48%

持股股東

佔比

Lynx1 Capital Advisors LLC

14.97%

BVF Partners L.P.

9.96%

K2 HealthVentures LLC

6.87%

Simplify Asset Management Inc

5.41%

Baker Bros. Advisors LP

5.31%

其他

57.48%

股東類型

持股股東

佔比

Investment Advisor

29.70%

Hedge Fund

21.44%

Venture Capital

11.33%

Investment Advisor/Hedge Fund

7.88%

Research Firm

2.72%

Individual Investor

0.39%

Bank and Trust

0.27%

其他

26.27%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

198

42.06M

80.16%

-7.95M

2025Q2

192

48.33M

92.38%

-952.90K

2025Q1

198

46.53M

88.95%

-3.07M

2024Q4

184

47.92M

91.75%

+202.11K

2024Q3

172

45.30M

92.65%

-3.14M

2024Q2

147

48.79M

100.07%

+12.56M

2024Q1

110

39.09M

88.67%

+3.45M

2023Q4

36.63M

84.04%

+3.23M

2023Q3

33.69M

84.61%

-2.13M

2023Q2

32.77M

82.58%

-787.78K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Lynx1 Capital Advisors LLC

7.86M

14.97%

-88.79K

-1.12%

Jun 30, 2025

BVF Partners L.P.

5.23M

9.96%

+336.60K

+6.88%

Jun 30, 2025

K2 HealthVentures LLC

3.60M

6.87%

+2.90M

+414.67%

Dec 31, 2024

Simplify Asset Management Inc

1.05M

Jun 30, 2025

Baker Bros. Advisors LP

2.78M

5.31%

Jun 30, 2025

The Vanguard Group, Inc.

2.15M

4.1%

-207.37K

-8.80%

Jun 30, 2025

abrdn Inc.

891.45K

1.7%

Jun 30, 2025

BlackRock Financial Management, Inc.

1.32M

2.51%

-529.55K

-28.71%

Jun 30, 2025

Bessemer Venture Partners

1.25M

2.37%

Jun 30, 2025

Alphabet, Inc.

1.08M

2.05%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Simplify Propel Opportunities ETF

1.72%

iShares Health Innovation Active ETF

0.13%

iShares Micro-Cap ETF

0.02%

iShares Biotechnology ETF

0.01%

Invesco Nasdaq Biotechnology ETF

0.01%

ProShares Ultra Nasdaq Biotechnology

0.01%

Invesco Dorsey Wright SmallCap Momentum ETF

DFA Dimensional US Sustainability Core 1 ETF

DFA Dimensional US Core Equity Market ETF

iShares Russell 3000 ETF

Simplify Propel Opportunities ETF

佔比1.72%

iShares Health Innovation Active ETF

佔比0.13%

iShares Micro-Cap ETF

佔比0.02%

iShares Biotechnology ETF

佔比0.01%

Invesco Nasdaq Biotechnology ETF

佔比0.01%

ProShares Ultra Nasdaq Biotechnology

佔比0.01%

Invesco Dorsey Wright SmallCap Momentum ETF

佔比0%

DFA Dimensional US Sustainability Core 1 ETF

佔比0%

DFA Dimensional US Core Equity Market ETF

佔比0%

iShares Russell 3000 ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

TScan Therapeutics Inc的前五大股東是誰？



TScan Therapeutics Inc的前五大股東如下：
Lynx1 Capital Advisors LLC
持有股份：7.86M
佔總股份比例：14.97%。
BVF Partners L.P.
持有股份：5.23M
佔總股份比例：9.96%。
K2 HealthVentures LLC
持有股份：3.60M
佔總股份比例：6.87%。
Simplify Asset Management Inc
持有股份：1.05M
佔總股份比例：2.00%。
Baker Bros. Advisors LP
持有股份：2.78M
佔總股份比例：5.31%。